Five Prime Therapeutics Inc

NASDAQ:FPRX  
22.34
-0.74 (-3.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)996.59M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$3.74 Million
Adjusted EPS-$0.53
See more estimates
10-Day MA$22.42
50-Day MA$18.59
200-Day MA$10.08
See more pivots

Five Prime Therapeutics, Inc. Stock, NASDAQ:FPRX

111 Oyster Point Boulevard, South San Francisco, California 94080-7047
United States of America
Phone: +1.415.365.5600
Number of Employees: 87

Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. Its product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.